Execution of Pharma Tariffs Brings These ETFs Into Focus
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
Zacks
Execution of Pharma Tariffs Brings These ETFs Into Focus
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
Zacks
More News
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
Zacks
Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
The FDA has told Novo that its review of the biologics license application is still underway and has not given a new date for a decision.
Stocktwits
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
NVO stock is down 11% this week, on track for its worst week since late February if losses hold.
Stocktwits
NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.
Stocktwits
Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
Trump's latest MFN drug-pricing deals create a mixed outlook for the broader healthcare sector ETFs.
Zacks
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Zacks
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Zacks
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
Zacks
NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future
Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.